These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 26162486)

  • 1. Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.
    Bambury RM; Rathkopf DE
    Urol Oncol; 2016 Aug; 34(8):348-55. PubMed ID: 26162486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).
    Gupta E; Guthrie T; Tan W
    BMC Urol; 2014 Jul; 14():55. PubMed ID: 25062956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
    Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
    Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
    Bernemann C; Schnoeller TJ; Luedeke M; Steinestel K; Boegemann M; Schrader AJ; Steinestel J
    Eur Urol; 2017 Jan; 71(1):1-3. PubMed ID: 27471164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of novel androgen receptor therapies in the real world: A nuanced approach.
    Dhawan M; Ryan CJ
    Urol Oncol; 2016 Aug; 34(8):340-7. PubMed ID: 27450893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer.
    Dellis AE; Papatsoris AG
    Expert Opin Pharmacother; 2019 Feb; 20(2):163-172. PubMed ID: 30462924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AR-V7 predicting treatment response in metastasized prostate cancer: has it peaked?
    Tsaur I; Borgmann H; Surcel CI; Ost P; Ploussard G
    World J Urol; 2018 Jan; 36(1):149-151. PubMed ID: 29086020
    [No Abstract]   [Full Text] [Related]  

  • 8. ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer.
    Fizazi K; Albiges L; Loriot Y; Massard C
    Expert Rev Anticancer Ther; 2015; 15(9):1007-17. PubMed ID: 26313416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor aberrations in the era of abiraterone and enzalutamide.
    Jentzmik F; Azoitei A; Zengerling F; Damjanoski I; Cronauer MV
    World J Urol; 2016 Mar; 34(3):297-303. PubMed ID: 26100946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer.
    McKay RR; Werner L; Fiorillo M; Roberts J; Heath EI; Bubley GJ; Montgomery RB; Taplin ME
    Clin Genitourin Cancer; 2017 Aug; 15(4):463-471. PubMed ID: 27890446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance emerges to second-generation antiandrogens in prostate cancer.
    Nelson WG; Yegnasubramanian S
    Cancer Discov; 2013 Sep; 3(9):971-4. PubMed ID: 24019330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer.
    Rajaram P; Rivera A; Muthima K; Olveda N; Muchalski H; Chen QH
    Molecules; 2020 May; 25(10):. PubMed ID: 32456317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.
    Belic J; Graf R; Bauernhofer T; Cherkas Y; Ulz P; Waldispuehl-Geigl J; Perakis S; Gormley M; Patel J; Li W; Geigl JB; Smirnov D; Heitzer E; Gross M; Speicher MR
    Int J Cancer; 2018 Sep; 143(5):1236-1248. PubMed ID: 29574703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].
    Neuzillet Y; Flamand V; Lebdai S; Villers A; Lebret T
    Prog Urol; 2013 Oct; 23 Suppl 1():S34-43. PubMed ID: 24314737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.
    Zhang T; Zhu J; George DJ; Armstrong AJ
    Expert Opin Pharmacother; 2015 Mar; 16(4):473-85. PubMed ID: 25534660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations.
    De Maeseneer DJ; Van Praet C; Lumen N; Rottey S
    Urol Oncol; 2015 Jul; 33(7):310-21. PubMed ID: 25708954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Lolli C; De Lisi D; Conteduca V; Gurioli G; Scarpi E; Schepisi G; Ravaglia G; Menna C; Farolfi A; Altavilla A; Burgio SL; Tonini G; Santini D; De Giorgi U
    Prostate; 2019 Aug; 79(11):1211-1220. PubMed ID: 31251826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.
    Joseph JD; Lu N; Qian J; Sensintaffar J; Shao G; Brigham D; Moon M; Maneval EC; Chen I; Darimont B; Hager JH
    Cancer Discov; 2013 Sep; 3(9):1020-9. PubMed ID: 23779130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?
    Antonarakis ES
    Expert Rev Anticancer Ther; 2015 Feb; 15(2):143-5. PubMed ID: 25547524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.